Mol Genet Metab Rep. 2020 Dec;25
100642
In de novo purine biosynthesis (DNPS), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (EC 2.1.2.3)/inosine monophosphate cyclohydrolase (EC 3.5.4.10) (ATIC) catalyzes the last two reactions of the pathway: conversion of 5-aminoimidazole-4-carboxamide ribonucleotide [aka Z-nucleotide monophosphate (ZMP)] to 5-formamido-4-imidazolecarboxamide ribonucleotide (FAICAR) then to inosine monophosphate (IMP). Mutations in ATIC cause an untreatable and devastating inborn error of metabolism in humans. ZMP is an adenosine monophosphate (AMP) mimetic and a known activator of AMP-activated protein kinase (AMPK). Recently, a HeLa cell line null mutant for ATIC was constructed via CRISPR-Cas9 mutagenesis. This mutant, crATIC, accumulates ZMP during purine starvation. Given that the mutant can accumulate ZMP in the absence of treatment with exogenous compounds, crATIC is likely an important cellular model of DNPS inactivation and ZMP accumulation. In the current study, we characterize the crATIC transcriptome versus the HeLa transcriptome in purine-supplemented and purine-depleted growth conditions. We report and discuss transcriptome changes with particular relevance to Alzheimer's disease and in genes relevant to lipid and fatty acid synthesis, neurodevelopment, embryogenesis, cell cycle maintenance and progression, extracellular matrix, immune function, TGFβ and other cellular processes.
Keywords: 5-aminoimidazole-4-carboxamide ribonucleoside, (AICAr); 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase, (ATIC); 5-aminoimidazole-4-carboxamide ribonucleotide, (ZMP); 5-formamido-4-imidazolecarboxamide ribonucleotide, (FAICAR); AICA-ribosiduria; AMP-activated protein kinase, (AMPK); Alzheimer's disease; Development; Purine synthesis; RNA-seq; Tuberous Sclerosis Complex 1 and 2, (TSC1 and TSC2); adenine phosphoribosyltransferase, (APRT); adenosine monophosphate, (AMP); adenosine triphosphate, (ATP); adenylosuccinate lyase, (ADSL); arachidonic acid, (AA); cyclooxygenase, (COX); cytochrome, P450 (CYP); cytosolic phospholipase A2, (cPLA2); de novo purine synthesis, (DNPS); differentially expressed gene, (DEG); false discovery rate, (FDR); fatty acid amide hydrolase, (FAAH); fetal calf macroserum, (FCM); fetal calf serum, (FCS); fragments per kilobase of exon per million reads mapped, (FPKM); gene ontology, (GO); guanosine monophosphate, (GMP); inosine monophosphate, (IMP); interferon, (INF); lipoxygenase, (LOX); mammalian Target of Rapamycin, (mTOR); minus adenine crATIC to minus adenine WT comparison, (MM); phospholipase, (PLA); phosphoribosyl pyrophosphate, (PRPP); phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase, (PAICS); plus adenine crATIC to plus adenine WT comparison, (PP); xanthine monophosphate, (XMP)